Skip to main content
Premium Trial:

Request an Annual Quote

RheoGene Names Hood, Ashburner to Scientific Advisory Board

NEW YORK, May 30 – RheoGene, a privately held gene expression company based in Charlottesville, Va., announced Wednesday that it had appointed several genomics industry heavyweights to its scientific advisory board.

Michael Ashburner, the joint head of the European Molecular Biology Laboratory and the European Bioinformatics Institute, and Leroy Hood, director of the Institute for Systems Biology, were both named to the board as was Jeffrey Trent, scientific director of the National Human Genome Research Institute.

Aaron Shatkin, director of the Center for Advanced Biotechnology and Medicince, will serve as chairman of the scientific advisory board.

"We are very pleased that these leading scientists have agreed to help guide research and discovery for RheoGene's products and technologies," Mohan Philip, RheoGene's chief scientific officer, said in a statement.

RheoGene has developed RheoSwitch, a gene expression technology that can turn gene expression on and off and allow it to be dialed up and down. The technology can be applied in proteomics, functional genomics, systems biology, and bioinformatics.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.